Skip to main content

Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.

Publication ,  Journal Article
Collier, W; Inker, LA; Haaland, B; Appel, GB; Badve, SV; Caravaca-Fontán, F; Chalmers, J; Floege, J; Goicoechea, M; Imai, E; Jafar, TH ...
Published in: Clinical journal of the American Society of Nephrology : CJASN
February 2023

The GFR slope has been evaluated as a surrogate end point for kidney failure in meta-analyses on a broad collection of randomized controlled trials (RCTs) in CKD. These analyses evaluate how accurately a treatment effect on GFR slope predicts a treatment effect on kidney failure. We sought to determine whether severity of CKD in the patient population modifies the performance of GFR slope.We performed Bayesian meta-regression analyses on 66 CKD RCTs to evaluate associations between effects on GFR slope (the chronic slope and the total slope over 3 years, expressed as mean differences in ml/min per 1.73 m2/yr) and those of the clinical end point (doubling of serum creatinine, GFR <15 ml/min per 1.73 m2, or kidney failure, expressed as a log-hazard ratio), where models allow interaction with variables defining disease severity. We evaluated three measures (baseline GFR in 10 ml/min per 1.73 m2, baseline urine albumin-to-creatinine ratio [UACR] per doubling in mg/g, and CKD progression rate defined as the control arm chronic slope, in ml/min per 1.73 m2/yr) and defined strong evidence for modification when 95% posterior credible intervals for interaction terms excluded zero.There was no evidence for modification by disease severity when evaluating 3-year total slope (95% credible intervals for the interaction slope: baseline GFR [-0.05 to 0.03]; baseline UACR [-0.02 to 0.04]; CKD progression rate [-0.07 to 0.02]). There was strong evidence for modification in evaluations of chronic slope (95% credible intervals: baseline GFR [0.02 to 0.11]; baseline UACR [-0.11 to -0.02]; CKD progression rate [0.01 to 0.15]).These analyses indicate consistency of the performance of total slope over 3 years, which provides further evidence for its validity as a surrogate end point in RCTs representing varied CKD populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clinical journal of the American Society of Nephrology : CJASN

DOI

EISSN

1555-905X

ISSN

1555-9041

Publication Date

February 2023

Volume

18

Issue

2

Start / End Page

183 / 192

Related Subject Headings

  • Urology & Nephrology
  • Renal Insufficiency, Chronic
  • Renal Insufficiency
  • Kidney Failure, Chronic
  • Humans
  • Glomerular Filtration Rate
  • Disease Progression
  • Biomarkers
  • 4202 Epidemiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Collier, W., Inker, L. A., Haaland, B., Appel, G. B., Badve, S. V., Caravaca-Fontán, F., … Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)*, . (2023). Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clinical Journal of the American Society of Nephrology : CJASN, 18(2), 183–192. https://doi.org/10.2215/cjn.0000000000000050
Collier, Willem, Lesley A. Inker, Benjamin Haaland, Gerald B. Appel, Sunil V. Badve, Fernando Caravaca-Fontán, John Chalmers, et al. “Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.Clinical Journal of the American Society of Nephrology : CJASN 18, no. 2 (February 2023): 183–92. https://doi.org/10.2215/cjn.0000000000000050.
Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, et al. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clinical journal of the American Society of Nephrology : CJASN. 2023 Feb;18(2):183–92.
Collier, Willem, et al. “Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.Clinical Journal of the American Society of Nephrology : CJASN, vol. 18, no. 2, Feb. 2023, pp. 183–92. Epmc, doi:10.2215/cjn.0000000000000050.
Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)*. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clinical journal of the American Society of Nephrology : CJASN. 2023 Feb;18(2):183–192.

Published In

Clinical journal of the American Society of Nephrology : CJASN

DOI

EISSN

1555-905X

ISSN

1555-9041

Publication Date

February 2023

Volume

18

Issue

2

Start / End Page

183 / 192

Related Subject Headings

  • Urology & Nephrology
  • Renal Insufficiency, Chronic
  • Renal Insufficiency
  • Kidney Failure, Chronic
  • Humans
  • Glomerular Filtration Rate
  • Disease Progression
  • Biomarkers
  • 4202 Epidemiology
  • 3202 Clinical sciences